SUPN:NASDAQSupernus Pharmaceuticals, Inc. Analysis
Data as of 2026-09-01 - not real-time
$44.21
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
At $44.21, Supernus Pharmaceuticals, Inc. shows a bearish moving-average alignment, with shorter averages beneath longer ones. It has lost 6.8% over the past 30 days. Relative strength is 40.2 — neutral — and the MACD signal is bearish. Recent trading has carved out support near $42.63 and resistance around $49.82.
On valuation the read is undervalued — earnings multiple of 9.9 versus a 30.4 sector average, below the peer group. Analyst price targets sit 39.7% above the current price. Revenue is growing at 32.4% on a -13.2% profit margin.
The composite risk read is 6/10, putting it in elevated territory. With 30-day volatility of 40.4%, a beta of 0.42 and a maximum drawdown of 24.1%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Near-term and long-term part ways here — hold short-term against buy longer out, with 4/10 conviction on the long call.
On valuation the read is undervalued — earnings multiple of 9.9 versus a 30.4 sector average, below the peer group. Analyst price targets sit 39.7% above the current price. Revenue is growing at 32.4% on a -13.2% profit margin.
The composite risk read is 6/10, putting it in elevated territory. With 30-day volatility of 40.4%, a beta of 0.42 and a maximum drawdown of 24.1%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Near-term and long-term part ways here — hold short-term against buy longer out, with 4/10 conviction on the long call.
Top Market Events
Hosted on MSN28dSupernus shares jump after revenue beat, higher guidance and Indivior merger announcementSupernus...Supernus Pharmaceuticals Inc SUPN raises full-year guidance on robust GOCOVRI and Qelbree sales, while advancing key...Specialty pharmaceutical company Supernus Pharmaceuticals NASDAQ:SUPN reported Q2 CY2026 results , with sales up 32.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 3/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 48.52
- MACD momentum is negative
Medium Term
1–3 yearsNeutral
Model confidence: 2/10
Key Factors
- Short-term moving averages stacked below long-term ones
- P/E of 9.9 versus sector average of 30.4
- Trading below the 200-day average of 48.52
Long Term
> 3 yearsPositive
Model confidence: 4/10
Key Factors
- P/E of 9.9 versus sector average of 30.4
- Negative profit margin of -13.2%
- Analyst targets imply +39.7% versus the current price
Key Metrics & Analysis
Financial Health
Revenue Growth32.40%
Profit Margin-13.23%
P/E Ratio9.9
ROE-10.49%
ROA0.39%
Debt/Equity3.90
P/B Ratio2.5
Op. Cash Flow$19.9M
Free Cash Flow$84.6M
Industry P/E30.4
Technical Analysis
TrendBearish
RSI40.2
Support$42.63
Resistance$49.82
MA 20$46.42
MA 50$46.74
MA 200$48.52
MACDBearish
VolumeDecreasing
Fear & Greed Index93.38
Valuation
Fair Value$56.20
Target Price$61.75
Upside/Downside39.67%
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.42
Volatility40.41%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.